Bright Minds Biosciences Income Statement

Financials in millions CAD. Fiscal year is October - September.

Millions CAD. Fiscal year is Oct - Sep.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2019 - 2020
Period Ending	Sep '25 Sep 30, 2025	Sep '24 Sep 30, 2024	Sep '23 Sep 30, 2023	Sep '22 Sep 30, 2022	Sep '21 Sep 30, 2021	2019 - 2020
Selling, General & Admin	2.53	1.45	2.2	2.55	2.31	Upgrade
Research & Development	11.08	1.18	5	12.18	6.31	Upgrade
Operating Expenses	13.61	2.63	7.2	14.73	8.62	Upgrade
Operating Income	-13.61	-2.63	-7.2	-14.73	-8.62	Upgrade
Interest Expense	-0.04	-	-	-	-	Upgrade
Interest & Investment Income	1.52	0.03	-	-	-	Upgrade
Currency Exchange Gain (Loss)	0.19	-0.01	0.01	0.01	0.15	Upgrade
Other Non Operating Income (Expenses)	-0.29	-0.2	-0.19	-0.24	-0.18	Upgrade
EBT Excluding Unusual Items	-12.23	-2.8	-7.37	-14.96	-8.65	Upgrade
Asset Writedown	-	-	-	-0	-	Upgrade
Pretax Income	-12.23	-2.8	-7.37	-14.96	-8.65	Upgrade
Net Income	-12.23	-2.8	-7.37	-14.96	-8.65	Upgrade
Net Income to Common	-12.23	-2.8	-7.37	-14.96	-8.65	Upgrade
Shares Outstanding (Basic)	7	4	4	2	2	Upgrade
Shares Outstanding (Diluted)	7	4	4	2	2	Upgrade
Shares Change (YoY)	59.58%	15.87%	50.58%	37.64%	148.42%	Upgrade
EPS (Basic)	-1.78	-0.65	-1.98	-6.06	-4.82	Upgrade
EPS (Diluted)	-1.78	-0.65	-1.98	-6.06	-4.82	Upgrade
EBIT	-13.61	-2.63	-7.2	-14.73	-8.62	Upgrade

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q